InsiderSignalSign in

← Insider buys

MXCT

MaxCyte, Inc. · Healthcare

No insider bought or sold MaxCyte, Inc. in the last 12 months

$0Bought, 12 mo

$0Sold, 12 mo

$144.5MMarket cap

MXCT over the last year

No insider buys filed in this year

MXCT after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Every filing

43 insider filings since 2021, newest first

Douglas J Swirsky · CFO

$65K+45.0%Aug 13

Maher Masoud · President and CEO

$103K+75.0%Aug 13

Stanley C Erck · Director

$137K+34.0%Aug 13

Richard Douglas · Director

$111K+53.0%Aug 13

William W Brooke · Director

$65K+50.0%Aug 13

Stanley C Erck · Director

$177K−15.0%Nov 5

Stanley C Erck · Director

$179K−15.0%Oct 2

Stanley C Erck · Director

$192K−15.0%Sep 5

Thomas M. Ross · EVP, Global Sales

$148K−57.0%Aug 5

Thomas M. Ross · EVP, Global Sales

$134K−57.0%Jul 10

John Joseph Johnston · Director

$40K−7.0%Jul 1

Thomas M. Ross · EVP, Global Sales

$136K−57.0%Jun 24

Maher Masoud · President and CEO

John Joseph Johnston · Director

$26K−4.0%Jan 30

Douglas Doerfler · President and CEO

$639K−27.0%Dec 6

Douglas Doerfler · President and CEO

$128K−7.0%Dec 1

John Joseph Johnston · Director

$37K−8.0%Nov 16

Douglas Doerfler · President and CEO

$151K−8.0%Jul 12

John Joseph Johnston · Director

$67K−11.0%Jun 28

Douglas Doerfler · President and CEO

$221K−12.0%Jun 15

Douglas Doerfler · President and CEO

$81K−5.0%May 5

Thomas M. Ross · EVP, Global Sales, Marketing

$71K−100.0%Apr 12

Douglas Doerfler · President and CEO

$75K−4.0%Apr 12

Thomas M. Ross · EVP, Global Sales, Marketing

$172K−100.0%Apr 7

Douglas Doerfler · President and CEO

$175K−9.0%Apr 7

Thomas M. Ross · EVP, Global Sales, Marketing

$50K−100.0%Apr 4

Douglas Doerfler · President and CEO

$51K−3.0%Apr 4

Thomas M. Ross · EVP, Global Sales, Marketing

$167K−100.0%Feb 3

Douglas Doerfler · President and CEO

$172K−8.0%Feb 3

Douglas Doerfler · President and CEO

$152K−8.0%Jan 5

Thomas M. Ross · EVP, Global Sales, Marketing

$148K−100.0%Jan 5

Thomas M. Ross · EVP, Global Sales, Marketing

$169K−100.0%Dec 6

Thomas M. Ross · EVP, Global Sales, Marketing

$202K−100.0%Nov 3

Thomas M. Ross · EVP, Global Sales, Marketing

$188K−100.0%Oct 12

Casdin Partners Master Fund, L.P. · 10% owner

$4.5M−7.0%Oct 5

Casdin Partners Master Fund, L.P. · 10% owner

$13.9M−23.0%Jul 6

Richard Douglas · Director

Maher Masoud · EVP and General Counsel

$923K−100.0%Nov 16

Amanda Louise Murphy · CFO

$1.8M−100.0%Nov 16

Thomas M. Ross · EVP, Global Sales

$1.5M−100.0%Nov 16

Ron Holtz · SVP and CAO

$1.8M−54.0%Nov 16

Douglas Doerfler · President and CEO

$3.7M−47.0%Nov 16

Casdin Partners Master Fund, L.P. · 10% owner

$23.4M+15.0%Aug 3

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.